Another press release about ALT-711 the AGE and Crosslink breaker!

ufotruth at ix.netcom.com ufotruth at ix.netcom.com
Mon Nov 9 17:04:00 EST 1998


I found the following press release at the following URL:


It sure does sound like ALT-711 will be very theraputic to human
beings and will most definantly have anti-aging benefits! Actually
both human beings with or without diabetes may benefit from this drug!
The only thing that I wish Alteon would have included in this press
release is more information about the other effects of ALT-711 like
increased skin elasticity and hydration and perhaps any preliminary
results from their phase 1 human trials.

Take care and have a great day.



Alteon Inc. (ticker: ALTN, exchange: NASDAQ) News Release - Monday,
November 09, 1998 
Alteon Compound Found to Reduce Arterial Stiffness in Old Primates 

RAMSEY, N.J., Nov. 9 /PRNewswire/ -- Alteon Inc. (Nasdaq: ALTN - news)
today announced that researchers from The National Institute on Aging
(NIA) and the Johns Hopkins Geriatric Center released a new study
demonstrating the ability of ALT-711 to reduce arterial stiffness in
elderly Rhesus monkeys. These results were presented at the 71st
Scientific Sessions of the American Heart Association (AHA) in Dallas,

Advanced Glycosylation End-products, or A.G.E.s, are formed as a
result of glucose chemically reacting with proteins. A.G.E. formation,
which occurs normally with aging and is accelerated in diabetes,
induces crosslinking of proteins like collagen and elastin. There is a
growing belief that this process is a causative factor in many of the
complications of diabetes and age-related diseases, including arterial
stiffness. ALT-711, Alteon's lead A.G.E. crosslink breaker in a novel
class of agents, catalytically breaks the A.G.E. crosslinks between
proteins, potentially leading to a reversal of the deterioration of
the cardiovascular system seen with aging. 

``A Novel Collagen Crosslink Breaker Effects a Sustained Reduction in
Arterial Stiffness in Old Primates'' was presented at the AHA meeting
in an oral presentation by Peter V. Vaitkevicius, M.D., Assistant
Professor, Division of Geriatric Medicine and Gerontology, Johns
Hopkins School of Medicine. Dr. Vaitkevicius and researchers in
collaboration with Edward G. Lakatta, M.D., Chief of the NIA
Laboratory of Cardiovascular Science, tested ALT-711 by measuring
pulse wave velocity (PWV) in 6 old Rhesus monkeys prior to and
following administration of 1.0 mg/kg of ALT-711 over 3 weeks. Three
serial measurements of aortic stiffness were made prior to dosing and
at weeks 1, 3, 5 and 8 after dosing of ALT-711. ALT-711 was found to
significantly reduce aortic stiffness (p<0.001) by week 3 and
persisting through week 8. Baseline weight, fasting blood glucose,
creatinine and cholesterol did not change after treatment. 

``Arterial stiffening with advancing age plays a major role in
diseases such as atherosclerosis, hypertension, stroke and heart
failure in older people,'' said Dr. Lakatta. ``Safe therapy to prevent
or reduce arterial stiffening in humans would likely have substantial
implications in the morbidity and mortality of these diseases. If
clinical studies in humans bear out the results we have seen in
animals, substances like ALT-711 could be the breakthrough we've been
working toward to reverse some types of age-related heart and vessel
disease. The next few years of study will tell the tale, and we must
wait for those results.'' 

Phase I human clinical studies of ALT-711 have been ongoing since June
1998 in healthy volunteers at a clinical pharmacology center in
Europe. To date, 88 patients have been treated in this Phase I
program. Alteon plans to begin U.S. Phase II testing of ALT-711 during

``These results, from such well-respected outside investigators,
support the significance of our A.G.E. technology and this novel class
of agents,'' said James J. Mauzey, Chairman and Chief Executive
Officer of Alteon. ``We look forward to the initiation of Phase II
trials of ALT-711 to begin validating these important findings in

Alteon is a leader in the discovery and development of pharmaceutical
products for the treatment of the complications of diabetes and
age-related diseases. Alteon's proprietary technology focuses on
Advanced Glycosylation End-products, or A.G.E.s, formed as a result of
circulating blood glucose reacting with proteins. A.G.E.s have been
shown to be a causative factor in many of the complications of
diabetes and aging, including kidney disease, nerve damage,
atherosclerosis and retinopathy. Alteon's approach is to inhibit or
break A.G.E.s or their chemical crosslinks, thereby potentially
impacting the disease states associated with diabetes and aging. A
Phase III pivotal clinical trial evaluating Alteon's lead A.G.E.
formation inhibitor, pimagedine, in Type 1 diabetic patients with
progressive kidney disease has been recently completed. Results from
that trial are being analyzed at an independent statistical center and
are expected to be announced this quarter. Another Phase III trial of
pimagedine, in Type 1 and Type 2 diabetic patients with end-stage
renal disease, is ongoing. ALT-711, the company's lead A.G.E.
crosslink breaker, is in Phase I human clinical trials. Alteon is also
pursuing the development of a novel series of glucose lowering agent
(GLA) compounds. 

Any statements contained in this press release that relate to future
plans, events or performance are forward-looking statements that
involve risks and uncertainties including, but not limited to, those
relating to technology and product development, regulatory approval
processes, intellectual property rights and litigation, competitive
products, ability to obtain financing and other risks identified in
the Company's filings with the Securities and Exchange Commission.
Actual results, events or performances may differ materially. The
Company undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements that may be made to
reflect events or circumstances after the date hereof or the reflect
the occurrence of unanticipated results.

"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: Statements in this press release regarding Alteon Inc.'s
business which are not historical facts are "forward-looking
statements" that involve risks and uncertainties. For a discussion of
such risks and uncertainties, which could cause actual results to
differ from those contained in the forward-looking statements, see
"Risk Factors" in the Company's Annual Report or Form 10-K for the
most recently ended fiscal year. 

More information about the Ageing mailing list

Send comments to us at biosci-help [At] net.bio.net